Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.

HOME
>
論文・技術情報
>
Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.

アブストラクト
ジャーナル名	Journal of thrombosis and haemostasis : JTH
Pubmed追加日	2024/8/23
投稿者	Berkowitz, Callie; Wilson, Samuel; Key, Nigel S; Ellsworth, Patrick
組織名	Department of Medicine, Division of Hematology, University of North Carolina at;Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood;Research Center, Chapel Hill, North Carolina, USA.;Research Center, Chapel Hill, North Carolina, USA. Electronic address:;patrick_ellsworth@med.unc.edu.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/39174232/